Event News & Resources
New lateral flow test may detect Alzheimer’s decades early! In collaboration with Aptamer Group!
We are pleased to share a fantastic article by SelectScience® Baroness Susan Greenfield CBE, neuroscientist and founder of Neuro-Bio, has spent four decades developing a novel hypothesis on the origins of Alzheimer’s disease. Now, in collaboration with Aptamer Group,...
Neuro-Bio congratulates Mike Zurawski for his new role
After a productive period of Chairmanship since 2022, Neuro-Bio is pleased to share that Dr Michal Zurawski will be transitioning to the role of Chairman of the Commercial Advisory Board. We would like to thank Mike for his contribution during his time as Chairman and...
Craig Samuel joins Neuro-Bio
Neuro-Bio is delighted to announce its new Chairman, Craig Samuel. Craig is a highly experienced senior business and technology Executive, having held board NED and executive leadership positions in both private and public companies in the UK, USA, and Asia. Executive...
Adam Khan joins Neuro-Bio
Neuro-Bio is delighted to welcome Adam Khan as Student Scientist. Adam is a second-year pharmacology undergraduate at the University of Liverpool. He has a keen interest in drug action, neuropharmacology and the cell signalling pathways underlying neurodegeneration....
Unilever l Neuro-Bio l Press release
We are delighted to announce a press release between Unilever and Neuro-Bio sharing the following : Unilever and Neuro-Bio discover a novel marker of skin aging of possible relevance to Alzheimer's disease. In a pioneering discovery, scientists at Unilever and...
Marni Rajput joins Neuro-Bio
Neuro-Bio is delighted to welcome Marni Rajput as Executive Assistant to the CEO. Marni is excited and grateful to be given the opportunity to join the team at Neuro Bio. She is currently studying Biomedical science at university and strongly believe this course has...
Neuro-Bio’s manuscript accepted for publication
We are delighted to share that Neuro-Bio’s manuscript titled "A novel bioactive peptide, T14, selectively activates mTORC1 signalling: therapeutic implications for neurodegeneration and other rapamycin-sensitive applications", has been accepted for publication at the...